PMCB (PharmaCyte Biotech) E10: $-5.27 (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech E10?

PharmaCyte Biotech PMCB -0.30% 32 E10 is $-5.27 as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

PharmaCyte Biotech's adjusted earnings per share data for the three months ended in Jan. 2026 was $-0.170. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-5.27 for the trailing ten years ended in Jan. 2026.

During the past 3 years, the average E10 Growth Rate was 31.40% per year. During the past 5 years, the average E10 Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of PharmaCyte Biotech was 31.40% per year. The lowest was 3.20% per year. And the median was 19.90% per year.

As of today (2026-06-25), PharmaCyte Biotech's current stock price is $0.7588. PharmaCyte Biotech's E10 for the quarter that ended in Jan. 2026 was $-5.27. PharmaCyte Biotech's Shiller PE Ratio of today is .


PharmaCyte Biotech  (NAS:PMCB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


PharmaCyte Biotech E10 Related Terms


PharmaCyte Biotech E10 Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech E10 Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.43 -19.59 -19.80 -9.71 -6.33

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.60 -6.33 -6.07 -5.76 -5.27

PMCB vs IMNN, ACXP, ENVB: E10 Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Shiller PE Ratio falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaCyte Biotech's adjusted earnings per share data for the three months ended in Jan. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jan. 2026 (Change)*Current CPI (Jan. 2026)
=-0.17/325.2520*325.2520
=-0.170

Current CPI (Jan. 2026) = 325.2520.

PharmaCyte Biotech Quarterly Data

per share eps CPI Adj_EPS
201604 0.000 239.261 0.000
201607 -1.963 240.628 -2.653
201610 -1.721 241.729 -2.316
201701 -2.236 242.839 -2.995
201704 -9.068 244.524 -12.062
201707 -2.735 244.786 -3.634
201710 -2.795 246.663 -3.686
201801 -3.120 247.867 -4.094
201804 0.000 250.546 0.000
201807 -1.741 252.006 -2.247
201810 -1.438 252.885 -1.850
201901 -0.900 251.712 -1.163
201904 -1.493 255.548 -1.900
201907 -1.405 256.571 -1.781
201910 -1.207 257.346 -1.525
202001 -0.954 257.971 -1.203
202004 -0.639 256.389 -0.811
202007 -0.790 259.101 -0.992
202010 -0.620 260.388 -0.774
202101 -0.490 261.582 -0.609
202104 -0.610 267.054 -0.743
202107 -0.640 273.003 -0.762
202110 -0.060 276.589 -0.071
202201 -0.040 281.148 -0.046
202204 -0.060 289.109 -0.068
202207 -0.070 296.276 -0.077
202210 -0.090 298.012 -0.098
202301 -0.040 299.170 -0.043
202304 -0.010 303.363 -0.011
202307 -0.540 305.691 -0.575
202310 -0.260 307.671 -0.275
202401 -0.650 308.417 -0.685
202404 -0.330 313.548 -0.342
202407 1.900 314.540 1.965
202410 -0.390 315.664 -0.402
202501 -0.440 317.671 -0.451
202504 1.520 320.795 1.541
202507 -1.230 323.048 -1.238
202510 -1.240 0.000
202601 -0.170 325.252 -0.170

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-5.27 mean?
PharmaCyte Biotech (PMCB) has a E10 of $-5.27 as of Jan. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's E10 too high?
PharmaCyte Biotech's current E10 is $-5.27. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's E10 compare to IMNN and ACXP?
PharmaCyte Biotech's E10 of $-5.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current E10 is $-5.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current E10 of $-5.27. The current E10 is $-5.27. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current E10 is $-5.27 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price